Pioneer Hi-Bred v. Inari — Later Testing Confirms Enormous Enzyme Genus Is Not Enabled

Background

Pioneer owned U.S. Patent No. 11,371,055, which claimed a vast genus of enzymes designed to make crops resistant to two classes of herbicides. The claims combined a functional requirement—the ability to degrade both phenoxy and pyridyloxy auxin herbicides—with structural requirements including at least 85% sequence identity to a disclosed enzyme and an AAD-12 motif.

Inari challenged claims 1–33 in a post-grant review. The claimed genus encompassed approximately 2.4 × 10¹⁰⁶ possible enzyme species, while the patent gave only two working examples. Pioneer later tested eight enzymes meeting the structural limitations. Only two showed the claimed dual herbicide-degrading function, and even those showed weak activity. The Patent Trial and Appeal Board held every challenged claim unpatentable for lack of enablement.

The Court’s Holding

The Federal Circuit affirmed. The panel held that the Board could consider experimental results generated after the patent’s priority date when those results shed light on whether the original disclosure enabled the full claim scope. Pioneer may have forfeited its contrary argument by failing to raise it before the Board, but the argument also failed on the merits.

The court distinguished decisions barring the use of later-developed technology to demand that an earlier patent disclose inventions that did not yet exist. Here, every tested enzyme could have been made at the priority date; the later testing simply supplied evidence about whether the patent’s structural guidance reliably predicted the claimed function. Federal Circuit precedent permits such evidence to show that a specification lacks a representative number of working species.

Substantial evidence also supported the Board’s conclusion. Even applying the patent’s additional guidance left an enormous genus of about 1.23 × 10⁶⁶ species. The specification disclosed two examples, and Pioneer’s own testing showed that close structural similarity did not reliably predict dual herbicide-degrading activity. The Board therefore reasonably found that the patent failed to provide guideposts allowing skilled artisans to reach the claim’s full scope without undue experimentation.

Key Takeaways

• Post-priority experiments may be used to evaluate whether a patent’s original disclosure enabled its full claim scope.
• That use differs from judging an old disclosure against technology that did not exist at the priority date.
• Broad functional genus claims require commensurately broad teaching; a few examples may not enable an astronomically large class.
• A patent owner’s own test data can undermine enablement when claimed structural features do not reliably predict the required function.

Why It Matters

The decision applies the Supreme Court’s instruction that the more an inventor claims, the more the patent must enable. It is especially important for biotechnology patents that define a genus through a combination of sequence similarity and desired function. Structural thresholds alone may be insufficient when small sequence changes produce unpredictable results.

The ruling also clarifies an evidentiary point for post-grant and district-court litigation. Later testing is not automatically irrelevant merely because enablement is assessed as of the filing date. When the tested embodiments were available at that time, the results can reveal whether the patent actually taught skilled readers how to practice the claimed invention across its breadth.